Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Puma Biotechnology, Inc.NASDAQ: PBYI
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $19.8M rose 42.8% year over year, ahead of the +23.2% change in trailing-twelve-month research & development. Sequentially, it rose 17.5% from the prior quarter. Over 3 fiscal years it compounded at +5.9% a year.
Context
- Research & development amounted to 27.2% of revenue in FY2025, up 3.3 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +42.8% holds above the trailing-twelve-month pace of +23.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 62.07M USD
- Year-over-year change
- +13.0%
- 4-year CAGR
- -3.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.07M | +13.0% |
| FY2024 | 2024-12-31 | 54.94M | +9.0% |
| FY2023 | 2023-12-31 | 50.38M | -3.6% |
| FY2022 | 2022-12-31 | 52.24M | -27.3% |
| FY2021 | 2021-12-31 | 71.87M | — |
Research & Development vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.2% is the 2nd highest of 11, against a peer median of +2.3%.
- Research & development amounts to 29.9% of revenue for PBYI, versus a peer median of 167.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $152.48M USD | +14.3% | +7.7% | — | |
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $129.68M USD | +5.2% | +71.4% | — | |
| LTM Jun 2026 | $128.85M USD | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $123.67M USD | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $116.62M USD | -0.1% | +21.2% | — | |
| LTM Mar 2026 | $68M USD | +23.2% | +5.9% | 29.9% | |
| LTM Mar 2026 | $31.62M USD | -19.6% | +9.2% | 6022.3% | |
| LTM Mar 2026 | $30.06M USD | -37.6% | -19.5% | — | |
| LTM Mar 2026 | CA$19.63M CAD | +4.7% | +15.5% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥13.28M CNY | -94.8% | -61.3% | — |
| Peer median (excluding PBYI) | — | +2.3% | +9.3% | 167.8% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 253.16M | 228.03M | 235.64M | 230.47M | 228.37M |
| Cost of Revenue | 63.7M | 55.09M | 62.68M | 64.4M | 58.16M |
| Gross Profit | 189.45M | 172.94M | 172.96M | 166.06M | 170.21M |
| Gross Margin | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% |
| Research & Development | 71.87M | 52.24M | 50.38M | 54.94M | 62.07M |
| Selling, General & Admin | 116.29M | 89.98M | 89.31M | 80.16M | 71.21M |
| Operating Expenses | 188.16M | 149.22M | 140.32M | 135.1M | 132.92M |
| Depreciation & Amortization | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| EBITDA | (4.69M) | 21.89M | 47.52M | 48.08M | 53.34M |
| EBITDA Margin | -1.9% | 9.6% | 20.2% | 20.9% | 23.4% |
| Operating Income | 1.29M | 23.72M | 32.64M | 30.97M | 37.3M |
| Operating Margin | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% |
| Interest Income | 160K | 813K | 2.61M | 4.72M | 4.08M |
| Interest Expense | 12.81M | 11.59M | 13.33M | 12.45M | 6.62M |
| Other Income / Expenses | (30.09M) | (23.26M) | (9.97M) | (6.87M) | (1.52M) |
| Income Before Tax | (28.8M) | 457K | 22.67M | 24.1M | 35.78M |
| Pre-Tax Margin | -11.4% | 0.2% | 9.6% | 10.5% | 15.7% |
| Income Tax Expense | 324K | 455K | 1.08M | (6.18M) | 4.67M |
| Net Income | (29.13M) | 2K | 21.59M | 30.28M | 31.11M |
| Net Margin | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
| EPS (Basic) | (0.72) | 0.02 | 0.46 | 0.62 | 0.62 |
| EPS (Diluted) | (0.72) | 0.02 | 0.45 | 0.62 | 0.61 |
| Weighted Avg Shares | 40.64M | 44.67M | 47.13M | 48.65M | 50.01M |
| Weighted Avg Shares (Diluted) | 40.64M | 44.93M | 47.55M | 49.1M | 50.65M |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.